Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention

Genes(2020)10.3390/genes11091068Source: DataRank Database

Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention is a research paper published in Genes (2020). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.41)OA: goldTopics (52)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Alfi Yasmina ORCID,Gerrit J.A. Vos,Paul W.A. Janssen ORCID,Christian M. Hackeng,Johannes C. Kelder ORCID

Live enrichment

PubMed:32932966 PMC:PMC7564055 OpenAlex:https://openalex.org/W3085122625

National Institutes of Health

Grant: U01 HL105198

National Institutes of Health

Grant: R24 GM61374

St. Antonius Ziekenhuis

Grant: St Antonius Innovation Fund

Robert Bosch Stiftung

Grant: -

ZonMw

Grant: TopZorg grant

NHGRI NIH HHS

Grant: U24 HG010615

National Institutes of Health

Grant: 5R24GM061374-13

PharmGKB: From Association to Mechanism

National Institutes of Health

Grant: 5U01HL105198-10

Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) Study

FWCI

0.41

Citation Percentile

0.6%

Citation Trend

2021

2023

2024

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2073-4425/11/9/1068/pdf?version=1599823273

publisherhttps://www.mdpi.com/2073-4425/11/9/1068/pdf?version=1599823273

publisherhttps://www.mdpi.com/2073-4425/11/9/1068/pdf

journalhttps://doi.org/10.3390/genes11091068

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32932966

Fields of Study

Antiplatelet Therapy and Cardiovascular DiseasesLipoproteins and Cardiovascular HealthDiabetes Treatment and Management03 medical and health sciences0302 clinical medicine

MeSH Terms

ClopidogrelAgedAnticholesteremic AgentsBlood PlateletsCoronary Artery DiseaseFemaleHumansMalePlatelet Aggregation InhibitorsPolymorphism, GeneticCohort StudiesPPAR alphaCytochrome P-450 CYP3APercutaneous Coronary Intervention

Keywords

ClopidogrelFibratePercutaneous coronary interventionMedicineAspirinInternal medicineConventional PCIStatinP2Y12GastroenterologyPharmacologyMyocardial infarctionGenotypingPharmacogenomicsCYP3A4PPARPciPersonalized MedicineBlood PlateletsMaleCoronary Artery DiseaseArticleCohort StudiesGeneticsCytochrome P-450 CYP3AHumansGenetics(clinical)PPAR alphaAgedPolymorphism, GeneticAnticholesteremic AgentsFemalePlatelet Aggregation Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being